Rasamsonia species isolated from cystis fibrosis patients: MALDI-TOF/MS identification and antifungal susceptibility by EUCAST method by S. Jacob et al.
Rasamsonia species isolated from cystis fibrosis patients:
MALDI-TOF/MS identification and antifungal susceptibility
by EUCAST method
Submitted by claire.leroy on Tue, 05/12/2015 - 14:22
Titre Rasamsonia species isolated from cystis fibrosis patients: MALDI-TOF/MSidentification and antifungal susceptibility by EUCAST method
Type de
publication Communication
Type Communication sans actes dans un congrès
Année 2014
Langue Anglais
Date du
colloque 05-06/06/2014
Titre du
colloque
Third meeting of the ECMM/ISHAM Working group "Fungal respiratory infections
in Cystic Fibrosis" (Fri-CF)
Auteur
Jacob, S. [1], Giraud, Sandrine [2], Dannaoui, Eric [3], Leto, Julie [4], Mouhajir, A.
[5], Angebault, Cécile [6], Béretti, Jean-Luc [7], Favennec, Loïc [8], Bouchara, Jean-
Philippe [9], Bougnoux, Marie-Elisabeth [10]
Pays France
Ville Angers
Résumé en
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A wide variety of filamentous fungi are able to colonize respiratory tract of patients
with cystic fibrosis (CF). Recently, fungi of the genus Rasamsonia (formely
Geosmithia) have been described as a new emergent group of fungi pathogen in CF
patients. The genus Rasamsonia comprises nine species including Rasamsonia
argillacea (sensu lato) which is a complex of species (R. argillacea sensu stricto, R.
piperina , R. eburnea, and R. aegroticola). Only species belonging to species
complex R. argillacea have been yet isolated from patients with chronic
granulomatous disease and CF. Accurate identification at the species level of the
members of the Rasamsonia complex on the basis of morphology criteria is
challenging, and frequent misidentification with a Penicillium emersonii have been
reported.
Matrix-assisted laser desorption ionization (MALDI)-time of flight (TOF)/mass
spectrometry (MS) is a powerful tool to rapidly identify moulds at the species level.
We investigated the potential of this technology to discriminate Rasamsonia species.
Nine reference strains were used to build a reference database library. Profiles from
3-, 5- and 7-day-old cultures of each reference strain were analysed to identify
species-specific discriminating profiles. The database was tested for accuracy using
a set of 74 clinical isolates collected from 29 CF-patients in 4 French hospitals
(Rouen, Giens, Angers and Paris). For each isolate, the species identification
obtained using MALDI-TOF/MS was compared to this obtained by Diversilab
method. Our results showed a high reliability of the MALDI-TOF analysis.
Antifungal susceptibility testing was also performed for 20 isolates (identified as R.
argillacea, R. aegroticola or R. piperina) from 13 patients using the microdilution
broth reference method of the Antifungal Susceptibility Testing Subcommittee of
EUCAST. All isolates tested showed a high MIC of > 8 mg/L to voriconazole, and the
majority also showed high MICs to itraconazole (MIC > 8 mg/L), except for R.
piperina strains (MIC 0.5 - 1 mg/L). The susceptibility to amphotericin B was
variable (MIC: 0.5 - > 8 mg/L), with no specific distinction according to Rasamsonia
species. Finally, all isolates exhibited low MICs to micafungin (0.0312 - 0.125 mg/L).
Altogether, our results show that MALDI-TOF/MS is a powerful tool for rapid
identification of Rasamsonia species that cannot be currently identified by
morphological examination in the clinical setting, and confirm that the members of
R. argillacea complex, colonizing respiratory tract in CF patients, have a very low
susceptibility to available antifungal agents.
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